Bastide reports half-year sales of 265 ME at December 31, up 5.7% organically on the same period a year earlier (and +6.2% on a reported basis).

Business remained buoyant in the second quarter, with organic growth accelerating to +6.1%, after +5.2% in the first quarter.

In detail, the more technically-intensive activities (Respiratory, Nutrition-Perfusion-Stomatherapy), which now account for 60% of sales, posted organic growth of +10.4% in the second quarter, in line with that recorded in the first quarter.

The "Homecare" business remained stable in a market that has now returned to normal after the health crisis.

Against this backdrop, the Group is maintaining its 2023/2024 forecasts, targeting annual sales of around 530 ME (adjusted for the impact of the Distrimed disposal and excluding new external growth operations), with a target operating margin before non-recurring items at least equal to that achieved in 2022-2023, i.e. 8.4%,

. The Group also points out that debt reduction remains its priority, and that the recent Distrimed disposal was fully in line with this objective.

Bastide is still studying possible asset disposals that would no longer fit in with its strategy.


Copyright (c) 2024 CercleFinance.com. All rights reserved.